Abstract
Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.
| Original language | English |
|---|---|
| Pages (from-to) | 91-111 |
| Number of pages | 21 |
| Journal | Progress in Pediatric Cardiology |
| Volume | 12 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 12 2000 |
| Externally published | Yes |
Fingerprint
Keywords
- ACE inhibition
- Afterload reduction
- Congenital heart disease
- Congestive heart failure
- Pediatric
- Ventricular dysfunction
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents : A review. / Grenier, Michelle A.; Fioravanti, Joanne; Truesdell, Susie C.; Mendelsohn, Alan M.; Vermilion, Roger P.; Lipshultz, Steven E.
In: Progress in Pediatric Cardiology, Vol. 12, No. 1, 12.12.2000, p. 91-111.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents
T2 - A review
AU - Grenier, Michelle A.
AU - Fioravanti, Joanne
AU - Truesdell, Susie C.
AU - Mendelsohn, Alan M.
AU - Vermilion, Roger P.
AU - Lipshultz, Steven E
PY - 2000/12/12
Y1 - 2000/12/12
N2 - Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.
AB - Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.
KW - ACE inhibition
KW - Afterload reduction
KW - Congenital heart disease
KW - Congestive heart failure
KW - Pediatric
KW - Ventricular dysfunction
UR - http://www.scopus.com/inward/record.url?scp=0033646134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033646134&partnerID=8YFLogxK
U2 - 10.1016/S1058-9813(00)00061-8
DO - 10.1016/S1058-9813(00)00061-8
M3 - Article
AN - SCOPUS:0033646134
VL - 12
SP - 91
EP - 111
JO - Progress in Pediatric Cardiology
JF - Progress in Pediatric Cardiology
SN - 1058-9813
IS - 1
ER -